Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque ...

"We continue to progress and enroll patients with moderate-to-severe psoriasis in the pivotal Phase ... frequency and severity were similar across study arms, with the most common being upper ...

While itching is common during pregnancy, it’s important to stay informed and seek medical advice if symptoms worsen.

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a ...

Kate Moss turned heads in a bold black feathered coat as she arrived at the Tom Ford show during Paris Fashion Week on ...

"We continue to progress and enroll patients with moderate-to-severe psoriasis in the pivotal Phase ... frequency and severity were similar across study arms, with the most common being upper ...

Organon has shared positive results from a long-term extension (LTE) study of its Vtama (tapinarof) cream, 1% in atopic ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

From eczema to allergic reactions to bug bites, here’s what common skin rashes look like in photos, and the symptoms that can help you I.D. the condition.